Radiosensitization induced by vemurafenib;Radiosensibilisation induite par le vémurafénib

Cancer/Radiotherapie

Volumn 17, Issue 4, 2013, Pages 304-307

  Ducassou, A ^a   David, I ^a   Delannes, M ^a   Chevreau, C ^a   Sibaud, V ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Melanoma; Radiation recall; Radiation therapy; Radiosentitization; Vemurafenib

Indexed keywords

VEMURAFENIB;

ARTICLE; CLINICAL PRACTICE; HUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; RADIOTHERAPY;

MÉLANOME; MELANOMA; PHÉNOMÈNE DE RAPPEL; RADIATION RECALL; RADIATION THERAPY; RADIOSENSIBILISATION; RADIOSENTITIZATION; RADIOTHÉRAPIE; VÉMURAFÉNIB; VEMURAFENIB;

COMBINED MODALITY THERAPY; FATAL OUTCOME; FRACTURES, SPONTANEOUS; HAND-FOOT SYNDROME; HUMANS; INDOLES; INTERFERON-ALPHA; KERATOACANTHOMA; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; RADIODERMATITIS; RADIOTHERAPY, ADJUVANT; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SPINAL NEOPLASMS; SULFONAMIDES;

EID: 84880731456     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2013.04.004     Document Type: Article

References (22)

1. Burris H.A., Hurtig J. Radiation recall with anticancer agents. Oncologist 2010, 15:1227-1237.
2. Azria D., Magné N., Zouhair A., Castadot P., Culine S., Ychou M., et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005, 31:555-570.
3. Colombino M., Capone M., Lissia A., Cossu A., Rubino C., De Giorgi V., et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-2529.
4. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
5. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
6. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
7. Sibaud V., Lamant L., Maisongrosse V., Delord J.P. Effets indésirables cutanés des inhibiteurs de BRAF: revue systématique. Ann Dermatol Venereol 2013, 031. 10.1016/j.annder.2013.02.
8. Sinha R., Edmonds K., Newton-Bishop J.A., Gore M.E., Larkin J., Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012, 167:987-994.
9. Dummer R., Rinderknecht J., Goldinger S.M. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012, 366:480-481.
10. Kim Y.B., Jeung H.C., Jeong I., Lee K., Rha S.Y., Chung H.C., et al. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. J Radiat Res 2012, 54:52-60.
11. Girard N., Mornex F. Sorafénib et radiothérapie dans le carcinome hépatocellulaire. Cancer Radiother 2011, 15:77-80.
12. Chung C., Dawson L.A., Joshua A.M., Brade A.M. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010, 21:206-209.
13. Sambade M.J., Peters E.C., Thomas N.E., Kaufmann W.K., Kimple R.J., Shields J.M. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011, 98:394-399.
14. Alter M, Satzger I, Kapp A, Gutzmer R. Serious skin toxicity for the combination of B-RAF inhibitors and radiotherapy [abstract CO5]. Barcelone: 8e Congrès de l'European Association of demarto-oncology. 2012; Disponible à l'adresse: (accès le 3/6/2013). http://www.melanoma2012.com/program.
15. Boussemart L., Boivin C., Claveau J., Tao Y.G., Tomasic G., Routier E., et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013, 4200. 10.1001/jamadermatol.2013.42002013.
16. Peuvrel L., Quéreux G., Saint-Jean M., Brocard A., Drouet F., Thillays F., et al. Radiothérapie+vemurafenib: attention danger. Ann Dermatol 2013, 139:B96.
17. Kavanagh B., Harasaki Y., Waxweiler T., Gonzalez R., Lewis K., Chen C., et al. Safety and efficacy of vemurafenib combined with stereotactic radiosurgery for brain metastases in BRAF+ melanoma. Int J Radiat Oncol 2012, 84:S302.
18. Narayana A., Mathew M., Golfinos J.G., Parker E.C., Ott P. Use of vemurafenib, a BRAF inhibitor along with radiation therapy in melanoma brain metastasis. Int J Radiat Oncol 2012, 84:S302-S303.
19. Andreassen C.N., Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009, 92:299-309.
20. Chu E.Y., Wanat K.A., Miller C.J., Amaravadi R.K., Fecher L.A., Brose M.S., et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012, 67:1265-1272.
21. Boyd K.P., Vincent B., Andea A., Conry R.M., Hughey L.C. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012, 67:1375-1379.
22. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1dose-escalation trial. Lancet 2012, 379:1893-1901.